Repros Therapeutics reports Q4 and FY15 results

|About: Repros Therapeutics Inc. (RPRX)|By:, SA News Editor

Repros Therapeutics (RPRX +10.0%) Q4 results: Revenues: $8K (+166.7%); R&D Expense: $4.8M (-17.2%); SG&A: $1.4M (-17.6%); Net Loss: ($6.3M) (+14.9%); Loss Per Share: ($0.26) (+16.1%).

FY2015 results: Revenues: $11K (+22.2%); R&D Expense: $24.1M (-11.1%); SG&A: $5.1M (+5.6%); Net Income: ($29.2M) (+10.2%); Loss Per Share: ($1.20) (+13.7%); Quick Assets: $21.4M (-54.1%).

No guidance given.

Subscribe for full text news in your inbox